瘙痒性结节病(PN)的血浆蛋白质标记揭示了明显的炎症和神经病理学细分型:集群分析。
The blood proteomic signature of prurigo nodularis (PN) reveals distinct inflammatory and neuropathic endotypes: a cluster analysis.
发表日期:2023 Feb 15
作者:
Varsha Parthasarathy, Karen Cravero, Lillian Xu, Junwen Deng, Zhe Sun, Sarah M Engle, Jonathan T Sims, Angela J Okragly, Shawn G Kwatra
来源:
J Am Acad Dermatol
摘要:
结节性痒疹(PN)是一种极度搔痒,慢性炎症性皮肤病,对于PN患者全身性炎症的了解仍很有限。本研究的目的是表征PN患者血浆炎症生物标志物,探讨该疾病的表型。在这个横断面的研究中,对PN患者(n = 29)和健康对照组(n = 18)的血浆样本进行了Olink蛋白质组学分析。与对照组相比,PN患者血浆中存在8种循环性生物标志物的含量增加,包括肿瘤坏死因子(TNF)、C-X-C基序化学因子配体9(CXCL9)、白细胞介素-12B(IL-12B)和TNF受体超家族成员9(TNFRSF9)(p <0.05)。在簇1(n = 13)和簇2(n = 16)中确定了两种PN簇。与簇1相比,簇2的25种炎症标志物水平更高。与簇2相比,簇1中的患者有更高的椎髓病和脊柱间盘疾病的发病率(69%与25%,p = 0.03)。与簇1相比,簇2中的患者更可能有过敏的病史(簇2中38%,簇1中8%,p = 0.09)。小样本量限制了强有力的亚组分析。本研究提供了PN神经免疫偏向的表型证据,可以帮助临床医生管理对传统治疗无反应的PN患者。opyright © 2023. Published by Elsevier Inc.
Prurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease. Little is known about systemic inflammation in PN.To characterize plasma inflammatory biomarkers in PN patients and investigate the presence of disease endotypes.In this cross-sectional study, Olink proteomic analysis was performed on plasma samples from PN patients (n=29) and healthy controls (n=18).PN patients had increased levels of eight circulating biomarkers compared to controls, including tumor necrosis factor (TNF), C-X-C Motif Chemokine Ligand 9 (CXCL9), interleukin (IL)-12B, and TNF receptor superfamily member 9 (TNFRSF9) (p<0.05). Two PN clusters were identified in Cluster 1 (n=13) and Cluster 2 (n=16). Cluster 2 had higher levels of 25 inflammatory markers than cluster 1. Patients in Cluster 1 had a greater percentage of patients with a history of myelopathy and spinal disc disease compared to Cluster 2 (69% vs. 25%, p=0.03). Patients in Cluster 2 were more likely to have a history of atopy (38% in cluster 2 vs. 8% in cluster 1, p=0.09).Small sample size precludes robust subgroup analyses.This study provides evidence of neuroimmune-biased endotypes in PN and can aid clinicians in managing PN patients that are non-responsive to traditional therapies.Copyright © 2023. Published by Elsevier Inc.